A Comparative Study of Affibody, Panitumumab and EGF for Near-Infrared Fluorescence Imaging of EGFR- and EGFRvIII-Expressing Tumors

Aberrant overexpression and/or activation of epidermal growth factor receptor (EGFR) is associated with many types of cancers. While EGFR has been extensively studied as a molecular imaging target, information about the common in-frame deletion mutant, EGFRvIII (targeting) is lacking. This poster describes a comparative study using labeled tumor imaging agents; EGFR-specific affibody, therapeutic antibody panitumumab, and ligand EGF, for the detection of EGFR- and EGFRvIII-expressing Tumors.